Credit Suisse analyst Dominic Lunn raised the firm’s price target on Novartis to CHF 90 from CHF 80 and keeps an Underperform rating on the shares.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVS:
- Novartis announces positive opinion for Cosentyx in hidradenitis suppurativa
- Novartis to present Kisqali Phase III NATALEE trial data at ASCO
- Bristol-Myers adds new U.S. manufacturing facility for viral vector production
- Novartis announces results from Phase III APPOINT-PNH trial of iptacopan
- Novartis upgraded to Buy from Hold at Deutsche Bank